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Abstract
Background/aims: To evaluate the ability of the model for end-stage liver disease (MELD) in predicting
the post-hepatectomy outcome for hepatocellular carcinoma (HCC).hpb_067 351..357
Methods: Between 2001 and 2004, 69 cirrhotic patients with HCC underwent hepatectomy and the
results were retrospectively analysed. MELD score was associated with post-operative mortality and
morbidity, hospital stay and 3-year survival.
Results: Seventeen major and 52 minor resections were performed. Thirty-day mortality rate was 7.2%.
MELD  9 was associated with no peri-operative mortality vs. 19% when MELD > 9 (P < 0.02). Overall
morbidity rate was 36.23%; 48% when MELD > 9 vs. 25% when MELD  9 (P < 0.02). Median hospital
stay was 12 days [8.8 days, when MELD  9 and 15.6 days when MELD > 9 (P = 0.037)]. Three-year
survival reached 49% (66% when MELD  9; 32% when MELD > 9 (P < 0.01). In multivariate analysis,
MELD > 9 (P < 0.01), clinical tumour symptoms (P < 0.05) and American Society of Anesthesiologists
(ASA) score (P < 0.05) were independent predictors of peri-operative mortality; MELD > 9 (P < 0.01),
tumour size >5 cm (P < 0.01), high tumour grade (P = 0.01) and absence of tumour capsule (P < 0.01)
were independent predictors of decreased long-term survival.
Conclusion: MELD score seems to predict outcome of cirrhotic patients with HCC, after hepatectomy.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most common
malignancies worldwide. Its incidence is 1:500 000 and it is
strongly correlated with cirrhosis.1 The mainstay of treatment, in
patients with solitary HCC and good liver function, is hepatic
resection.2
Evolution in surgical techniques and peri-operative care have
improved post-operative outcome, in patients with severe under-
lying liver disease undergoing hepatectomy. The risk of hepatic
failure in a cirrhotic patient undergoing hepatectomy still remains
high, as a result of compromised function of the liver remnant.3,4
Therefore, a thorough evaluation of the hepatic function reserve is
necessary prior to surgical intervention, in order to select the best
candidates for hepatic resection among cirrhotic patients, with
reasonable post-operative morbidity and mortality.
Child–Pugh–Turcotte (CPT) classification was the first system-
atic approach used to determine the severity of cirrhosis and select
those patients who could tolerate hepatic resection.5 CPT class C is
considered an absolute contraindication for surgical treatment,
whereas only few hepatectomies are performed in class B
cirrhosis.5–7 CPT class A patients are generally considered good
candidates for hepatic resection and good post-operative outcome
is expected. More refined evaluation of the liver function reserve is
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often needed, as a result of limitations in the discriminatory
ability of the CPT system, as it uses subjective parameters, such as
ascites and encephalopathy.8–11
Many tests have been applied for the assessment of dynamic
hepatic function, such as the indocyanine green clearance test,9
lidocaine test,10 galactose elimination capacity,11 and it was shown
that they could provide a more refined estimate of hepatic func-
tion than the CPT score.9
The model for end-stage liver disease (MELD) score was
recently introduced to evaluate hepatic function reserve in cir-
rhotic patients.12–15 It has the advantage of using three objective
and easily measured parameters: creatinine levels, international
normalized ratio (INR) and total bilirubin.
MELD score is used for survival prediction in cirrhotic patients
receiving a transjugular intrahepatic portosystemic shunt.12 It has
also been used to determine priority on waiting lists for liver
transplantation13 and in predicting post-operative outcome of cir-
rhotic patients, undergoing surgical procedures.14,15
The aim of this study was to examine whether the pre-operative
MELD score can predict post-operative mortality, morbidity,
hospital stay and 3-year survival in cirrhotic class A patients
undergoing hepatectomy for HCC. An effort to subcategorize the
low-from the high-risk class A patients is provided.
Materials and methods
We retrospectively analysed the clinical records of all patients
with HCC, who underwent hepatic resection in our institution
between January 2001 and January 2004. Patients who were anti-
coagulated and those with chronic renal insufficiency requiring
haemodialysis were excluded from the study. HCC was pathologi-
cally confirmed in all patients included in the study. We identified
69 patients fulfilling the above criteria. Clinical and pathological
features of the patients are reported in Tables 1 and 2.
CPT class was calculated using prothrombin time, albumin,
bilirubin and clinical findings of ascites and encephalopathy.16
CPT score was stratified as class A (5–6), B (7–9) and C (10–15).
Sixty two patients were classified as CPT class A (89.8%) and seven
patients as CPT class B, score 7 (10.2%).
MELD score was calculated using pre-operative values of three
laboratory tests: INR for prothrombin time, serum total bilirubin
(TBil) and serum creatinine (Cr). MELD score was calculated
using the following formula: MELD = 9.57 ¥ loge(Cr mg/dl) +
3.78 ¥ loge(TBil mg/dl) + 11.20 ¥ loge(INR) + 6.43.12 We used the
MELD score of the patient upon admission to our clinic, as it
more accurately represents the severity of cirrhosis before surgery.
Median MELD score prior to surgery was nine (range, 6–15). The
distribution of MELD score in our population is shown in Fig. 1.
Patients with CPT class A cirrhosis showed a median MELD
score of 8, ranging from 6 to 14, significantly lower than patients
with CTP class B cirrhosis who had a median MELD score of 11
(range, 9–15, P < 0.05).
During hospitalization and prior to surgery, the majority of the
patients received blood products such as fresh frozen plasma
(FFP) in order to improve their laboratory values. Hepatitis activ-
ity and cirrhosis were evaluated using the Isaak fibrosis score.17
Necrosis and inflammatory changes characteristic of hepatitis
were scored as mild (0–5), moderate (6–12) or severe (13–18), and
fibrosis was scored as cirrhosis vs. Non-cirrhosis. Operative data
are shown in Tables 1 and 2. Major hepatic resection was defined
as the removal of three or more segments.18 Portal vein emboliza-
tion (PVE) was performed 6 to 8 weeks before surgery whenever
Table 1 Univariate analysis of peri-operative mortality in patients
with cirrhosis with hepatocellular carcinoma
Variable No. of
patients
Peri-operative
mortality, n (%)
P-value
Age (years) 0.6
65 41 2
>65 28 3
Gender 0.7
Male 49 4
Female 20 2
Symptoms <0.05
Present 28 5
Absent 41 0
CPT class 0.5
A 62 4
B 7 1
MELD score 0.01
9 43 0
>9 26 5
Tumour size >0.05
5 43 3
>5 26 2
Grade >0.05
1 5 0
2 36 3
3 28 2
4 0
Stage 0.1
1 22 2
2 26 2
3 19 1
Extent of resection 0.09
Minor 52 2
Major 17 3
ASA class <0.05
1 14 0
2 34 1
3 21 4
CPT, Child–Pugh–Turcotee; MELD, model for end-stage liver disease;
ASA, American Society of Anesthesiologists.
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the future liver remnant (FLR) was expected to be less than 40% of
the total liver volume (TLV) with the tumour volume subtracted
(as calculated using three-dimensional CT volumetry). Tumour
histological grading was assessed according to the criteria of
Edmondson and Steiner based on the areas of the tumour with the
highest grade.19 Tumours were classified accordingly to the sixth
edition of AJCC Cancer staging manual.20
Post-operative mortality was defined as any death occurring
within 30 days after surgery. The primary end point of the study
was the investigation of the relationship between the pre-
operative MELD score and the development of irreversible liver
failure after hepatectomy in cirrhotic patients. It was defined as a
growing impairment of liver function after resection, which led to
the death of the patient or required transplantation. The relation-
ship between the MELD score and post-operative complications
(morbidity), length of hospital stay and 3-year patient survival
represented secondary end points. Post-operative jaundice was
defined as a serum bilirubin level above 5 mg/dL, alteration of
coagulation factors was defined as considerable or severe, when a
FFP infusion was required in order for these to be corrected, and
renal impairment was defined as an increase in blood urea nitro-
gen above 2 g/l and/or an increase in serum creatinine above
2 mg/dl.
Hospital stay was computed from the date of the operation,
until discharge at home. Patient survival was computed from the
date of the operation, until the most recent follow-up. Controls
and patients still alive after the first year after surgery were cen-
sored at this time point; patients transplanted for post-operative
liver failure were censored the day prior to transplantation, and
patients who died from causes not related to liver failure were
censored the day prior to the event.
Long-term follow-up included serum a-fetoprotein (AFP) and
CT scan of the abdomen every 3 months during the first year after
surgery and at 6-month intervals thereafter. CT, MRI and PET
scan or angiography were performed selectively when recurrence
was suspected.
Statistical analysis
Continuous variables were expressed as median and range. The
values in the different subgroups were compared using the
Kruskal–Wallis test. Normal distribution could not be proven
for the clinical variables available (Kolmogorov–Smirnov test,
P < 0.05).
Non-parametric tests were applied to all the data analysis. Cat-
egorical variables were expressed as prevalence and subgroups
were compared using the c2 test with Yates’s correction. Survival
Table 2 Univariate analysis of clinicopathologic factors associated
with survival after hepatectomy for hepatocellular carcinoma in
patients with cirrhosis
Variable 1-year
survival (%)
3-year
survival (%)
P-value
Age (yr) 0.3
65 61 52
>65 69 43
Gender 0.6
Male 66 47
Female 64 58
Symptoms 0.01
Present 43 16
Absent 82 69
CTP class 0.6
A 66 46
B 51 50
MELD score 0.01
9 90 66
>9 49 32
Tumor size 0.01
5 79 69
>5 42 31
Grade 0.01
1 100 100
2 73 61
3 52 32
4 0 0
Stage 0.6
1 72 65
2 83 33
3 49 37
Extent of resection 0.06
Minor 74 52
Major 43 31
Capsule 0.01
Yes 72 52
No 33 14
MELD, model for end stage liver disease.
Figure 1 Distribution of model for end-stage liver disease (MELD) in
patients with cirrhosis
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probabilities were constructed using Kaplan–Meier survival esti-
mates and compared using the log-rank test.
The prognostic value of MELD in predicting post-operative
liver failure and complications was assessed using receiver-
operating characteristic (ROC) curve analysis. A significance level
of 0.05 was used in all analyses. ROC analysis was performed using
MedCalc Version 7.2.1.0 (Med-Calc Software, Mariakerke,
Belgium). The statistical analysis was done using SPSS Version
10.0 software (SPSS, Chicago, IL, USA).
Results
Surgery consisted of 52 (75.36%) minor hepatic resections and
17 (24.64%) major hepatic resections. Serum AFP was elevated
in 61% of patients with a mean level of 2211 ng/ml (range
1–25 000 ng/ml). Six right hepatectomies (8.6%), 11 left hepate-
ctomies (16%), 23 wedge resections (33.33%), 21 segmentecto-
mies (30.4%) and 8 left lateral sectionectomies (11.6%) were
performed.
Resection was performed using the conventional method with
hepatic inflow dissection and selective vascular pedicle ligation
followed by outflow short hepatic vein ligation in a piggyback
fashion. Intra-operative ultrasound was performed routinely in
patients undergoing hepatectomy. Median operating time was
195 min (range 150 to 310 min). In nine patients, ischaemic pre-
conditioning was performed by vascular inflow occlusion during
resection.
The mean size of HCC was 5.6 cm (range 1.5 to 14 cm). AJCC
stage was I in 22 patients, II in 26 patients and III in 19 patients.
All resections were performed with a tumour-free margin of at
least 1 cm.
Five patients (7.24%) developed irreversible post-operative
liver failure and died within 30 days after surgery. Four of these
patients were classified as CPT class A: two underwent a left hepa-
tectomy, one a right hepatectomy and one a right posterior
sectionectomy. One patient, classified as CTP class B, developed
post-operative liver failure after a wedge resection.
Patients who experienced post-operative liver failure had a
median MELD score of 10 (range, 9–15), significantly higher in
comparison to patients where this event did not occur (median, 7;
range, 6–13; P = 0.01). ROC analysis identified a MELD score
above nine as a satisfactory cut-off value for predicting post-
operative liver failure [area under the curve (AUC) = 0.92, 95%
CI = 0.87–0.96; sensitivity = 81%; specificity = 87%] (Fig. 2).
Univariate analysis identified a MELD score > 9 (P < 0.01),
presence of clinical tumour symptoms (P < 0.05) and ASA score
(P < 0.05) as significantly associated with peri-operative mortal-
ity. The peri-operative mortality was significantly higher when the
MELD score was above nine (P = 0.02). Other patients’ demo-
graphics and pathological factors were not associated with peri-
operative mortality (Table 1). Multivariate analysis demonstrated
that a MELD score > 9 (P < 0.01), clinical tumour symptoms
(P < 0.01) and ASA score (P < 0.051) are independent predictors
of peri-operative mortality.
Other less life-threatening complications than post-operative
liver failure included the occurrence of intractable ascites, requir-
ing intensive therapy with diuretics for remission, elevation of
INR > 2; 24-h post-surgery requiring a FFP transfusion and eleva-
tion of total bilirubin >5 mg/dl. Twenty-five patients (36.23%)
experienced at least one post-operative complication. Refractory
ascites developed in 10 cases (14.5%), jaundice in 7 cases (10.1%),
and alteration of coagulation factors in 12 cases (17.4%).
Patients who experienced post-operative complications, had
higher MELD scores (median, 10; range, 7–15) in comparison to
patients who did not experience any complication (median, 8;
range, 6–11; P = 0.001). ROC analysis again identified a MELD
score above nine as the best cut-off value for predicting occur-
rence of post-operative complications (AUC 0.84, 94% CI = 0.77–
0.88; sensitivity = 85%; specificity = 61%) (Fig. 3).
Patients were divided according to the cut-offs of the MELD
scores obtained by ROC analysis in two groups: MELD below or
equal to 9 and MELD above 9. MELD score was9 in 43 patients
(62.3%) and >9 in 26 patients (37.7%). The prevalence of post-
operative liver failure and the morbidity in relationship with the
MELD score prior to surgery as well as 3-year survival rates are
reported in Tables 1 and 2. Patients with a MELD score below or
equal to nine did not experience post-operative liver failure, they
had zero 30-day mortality and showed the lowest morbidity 25%
in contradiction to patients with MELD > 9, who had the highest
prevalence of post-operative liver failure and 30-day mortality
(19%) and the highest morbidity (48%) (P < 0.02 in both cases).
Mean hospital stay was 12 days. Patients with a MELD score
below or equal to nine were discharged from the hospital after a
median of 8.8 days (range, 6–15 days). When MELD score was
above nine, the median hospital stay reached 15.6 days (range
Figure 2 Receiver-operating characteristic (ROC) curve of the model
for end-stage liver disease (MELD) score in predicting post-
operative liver failure after hepatic resection in patients with cirrhosis
(AUC = 0.92, 95% CI = 0.87–0.96)
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9–27 days; P = 0.037). The 3-year survival for the entire cohort
reached 49%. The 3-year survival was 66% when MELD  9 and
32% when MELD > 9; P < 0.01 (Table 2).
Multivariate analysis revealed that MELD > 9 (P < 0.01),
tumour size > 5 cm (P < 0.01), high tumour grade (P = 0.01) and
absence of tumour capsule (P < 0.01) are independent predictors
of decreased long-term survival (Table 2).
Discussion
Liver failure after hepatectomy is one of the most severe compli-
cations of liver resection. In patients with liver cirrhosis, liver
failure after hepatectomy is even more common because of the
fact that resection removes functional liver tissue, from an organ
that is already functioning marginally.
Pre-operative assessment of liver function and prediction of
post-operative functional reserve are of paramount importance to
minimize surgical risk.
CPT is not always a reliable indicator of hepatic reserve and has
a limited role in predicting post-operative outcome.21
The MELD score seems to have the ability to categorize cir-
rhotic patients more accurately.22 A cirrhotic patient eligible for
resection on the basis of CTP score may not be resectable on the
basis of MELD. Such patients should be referred to non-surgical
approaches such as radiofrequency ablation or transarterial
chemoembolization. In our study most patients were class A (62
out of 69 patients: 89.8%) according to the CPT system. However,
MELD classification managed to identify pre-operatively those
class A patients with a higher 30-day mortality rate, greater risk of
developing a post-hepatectomy complication and having a longer
hospital stay and poorer long-term outcome.
Our study indicated that patients who underwent hepatectomy,
with a pre-operative MELD score > 9, had elevated 30-day mor-
tality rate (19% vs. 0%), high incidence of post-operative compli-
cations (48% vs. 25%), longer hospital stay (15.6 vs. 8.8 days) and
worse 3-year survival (32% vs. 66%) in comparison to patients
with a MELD score  9.
Conversely, patients with MELD scores below or equal to 9, who
represent the 62.3% of cirrhotic patients in the present study,
showed no post-operative liver failure, as well as low morbidity,
shorter hospital stays and a 100% survival rate, proving that a
good outcome can be achieved in these patients through hepatic
resection.
Several reports from different groups, including ours, consider
partial hepatectomy as a good option in well-compensated CPT
class A patients.23–26 In addition, liver resection has been considered
as a bridge to liver transplantation in order to reduce the dropout
rate in patients with HCC on cirrhosis on the waiting list.27
Patients with a MELD score equal to or above 11 probably
represent the ideal patients to refer for non-surgical approaches
such as thermal ablation or chemoembolization and, whenever
possible, for liver transplantation.
In particular, in the setting of liver transplantation, Merion
et al.28 showed that a threshold score of 11 patients in whom,
independent of HCC, transplantation is justified (above 11) or
futile (below 11); in particular, cirrhotic patients with a MELD
score between 6 and 11, were shown to have a post-transplant
mortality significantly higher than waiting list mortality. There-
fore, the results from recent studies may give support to a system-
atic transplantation policy in small HCC patients with a MELD
score exceeding 11 as well as partial hepatectomy in patients with
lower MELD scores.22 Even in patients with a MELD score
between 9 and 10, carefully consideration must be given in intra-
operative and post-operative management and major hepatecto-
mies should be avoided.
Our findings show that a MELD score > 9 is strongly predictive
of increased peri-operative mortality in patients with cirrhosis
undergoing hepatic resection for HCC. No other clinical and
pathological factors except for clinical tumour symptoms and
ASA score were predictive of peri-operative mortality. This is in
agreement with other reports in the field.21
Univariate analysis demonstrated that a MELD score > 9,
tumour size > 5, high tumour grade, micro-vascular invasion,
hepatitis C cirrhosis and the number of lesions are independent
predictors of decreased long-term survival. Moreover, subset
analysis of survival using the MELD score and tumour size iden-
tify patients who would potentially derive significant benefit from
resection despite the background cirrhosis. Interestingly we docu-
mented the MELD score utility in assessing long-term survival of
patients with HCC size > 5 cm as a major factor influencing
operative intervention.
The high recurrence rate in patients with higher MELD scores
can be explained by the different immunological status of these
patients (cytokines).29–31
Figure 3 ROC curve of the MELD score in predicting occurrence of
post-operative complication after hepatic resection in patients with
cirrhosis [area under the curve (AUC) = 0.85, 95% CI = 0.78–0.89]
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In our study, all patients had histological proved cirrhosis. The
MELD score’s reliability in predicting morbidity and mortality
after elective liver resection has been criticized in patients with
minimal or no evidence of liver disease.32
It is worth noting that there is a number of patients who, in
spite of a low MELD score, have advanced liver disease using
clinical evaluation and CTP score and therefore cannot be candi-
dates for resection. These are patients with intractable ascites, who
are malnourished and with encephalopathy, who have a very low
MELD score, but clearly in whom surgery would be too danger-
ous. CPT stage and clinical evaluation should always be the initial
consideration that precedes the MELD calculations. We must
remember that only CPT class A and B patients should be con-
sidered for resection in the first place.
Conclusion
MELD score can accurately predict mortality, morbidity and long-
term survival in patients with HCC and cirrhosis, undergoing
hepatic resection. Cirrhotic patients with a high MELD score have
an increased risk of post-operative liver failure and complications,
they are expected to have poorer long-term survival after liver
resection and should be referred for other treatments. Cirrhotic
patients with a low MELD score treated with minor hepatic resec-
tions achieve zero 30-day mortality and low morbidity rates,
whereas expected long-term survival is promising. Application of
a MELD score in the pre-operative assessment of liver function
prior to hepatic resection is recommended, as it facilitates identi-
fication of high-risk class A patients prior to hepatic resection
and selection of the best candidates for hepatectomy. A multi-
institutional study is required to better define the selection criteria
for hepatic resection in HCC patients with cirrhosis.
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